Skip to main content

Table 1 Baseline characteristics (n = 45)

From: Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients

Characteristicsa Value
Age, mean ± SD 66.2 ± 12.3
Sex
 Male 21 (46.7)
 Female 24 (53.3)
Body Mass Index, mean ± SD, kg/m2 23.2 ± 4.1
BMI categories, No. (%)
 Malnutrition b 7 (15.6)
 Normal 24 (53.3)
 Overweight c 14 (31.1)
ECOG PS, No. (%)
 0 12 (26.7)
 1 31 (68.9)
 2 2 (4.4)
mGPSd, No. (%)
 0 17 (43.6)
 1 17(43.6)
 2 5 (12.8)
Hospitalizations number, median [range] 10 [0–18]
Follow-up, median [range], days 167 [0–189]
Primary tumor location, No. (%)
 Colon and rectum 22 (48.9)
 Esophagus 3 (6.7)
 Stomach 5 (11.1)
 Biliary tract 1 (2.2)
 Pancreas 9 (20.0)
 Small intestine 1 (2.2)
 Neuroendocrine tumor 2 (4.4)
 Unknown 2 (4.4)
Stage, No. (%)
 Local 20 (44.4)
 Locally advanced 6 (13.3)
 Metastatic 19 (42.2)
Type of treatment, No. (%)
 Chemotherapy 38 (84.4)
 Chemotherapy and biotherapy 7 (15.6)
Chemotherapy protocol, No. (%)
 5FU + OXALIPLATIN 22 (48.9)
 5FU + IRINOTECAN + OXALIPLATIN 7 (15.6)
 5FU alone 6 (13.3)
 GEMCITABINE 5 (11.1)
 5FU-DACARBAZINE 2 (4.4)
 5FU + IRINOTECAN 1 (2.2)
 GEMCITABINE + OXALIPLATIN 1 (2.2)
 VP16 + CISPLATINE 1 (2.2)
Neurotoxic chemotherapy e, No. (%) 31 (68.9)
Biotherapy protocol, No. (%)
 BEVACIZUMAB 6/7 (85.7)
 CETUXIMAB 1/7 (14.3)
Dynapenia, No. (%) 11 (24.4)
  1. SD standard deviation, BMI body mass index, mGPS modified Glasgow Prognostic Score, ECOG PS Eastern Cooperative Oncology Group Criteria Performance Status
  2. aData are expressed as No (%) unless otherwise indicated
  3. bmalnutrition was defined as BMI < 21 kg/m2 in patients aged more than 70 years old and BMI < 18.5 kg/m2 in patients aged less than 70 years old
  4. coverweight was defined as BMI > 25 kg/m2
  5. d6 missing data
  6. eneurotoxic regimens: 5FU + IRINOTECAN+OXALIPLATIN, 5FU + OXALIPLATIN,GEMCITABINE + OXALIPLATIN; VP16-CISPLATINE